Quarterly ResultMay 13, 2026, 04:14 PM
INOVIO Q1 Net Loss $(19.7)M; INO-3107 FDA PDUFA Oct 30, 2026
AI Summary
INOVIO reported a Q1 2026 net loss of $(19.7) million, consistent with the prior year, and an improved net loss per share of $(0.28). The company's Biologics License Application for INO-3107, a treatment for Recurrent Respiratory Papillomatosis (RRP), is under active FDA review with a target PDUFA date of October 30, 2026, and commercial readiness plans are advancing. INOVIO also announced a clinical trial collaboration for INO-5412 in glioblastoma and strengthened its balance sheet with a $16.0 million equity offering in April 2026, extending its cash runway into Q1 2027.
Key Highlights
- INO-3107 Biologics License Application (BLA) is under active FDA review with a target PDUFA date of October 30, 2026.
- Net loss for Q1 2026 was $(19.7) million, consistent with $(19.7) million for Q1 2025.
- Net loss per basic and diluted share improved to $(0.28) in Q1 2026 from $(0.51) in Q1 2025.
- Research and Development (R&D) expenses decreased to $14.1 million in Q1 2026 from $16.1 million in Q1 2025.
- General and Administrative (G&A) expenses decreased to $7.9 million in Q1 2026 from $9.0 million in Q1 2025.
- Cash, cash equivalents, and short-term investments were $37.7 million as of March 31, 2026.
- Raised approximately $16.0 million in net proceeds from a public equity offering in April 2026.
- Current cash is anticipated to fund operations into Q1 2027, beyond the INO-3107 PDUFA date.